Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact

Citations to this article

New therapy to revert dysfunctional antibody responses during HIV-1 infection
Francesca Chiodi
Francesca Chiodi
Published October 25, 2010
Citation Information: J Clin Invest. 2010;120(11):3810-3813. https://doi.org/10.1172/JCI44872.
View: Text | PDF
Commentary

New therapy to revert dysfunctional antibody responses during HIV-1 infection

  • Text
  • PDF
Abstract

Individuals infected with HIV-1 progress to AIDS at different rates. Rapid progressors develop AIDS within 2–5 years of initial infection, compared with approximately 10 years in typical progressors. Progression to AIDS is associated with impaired humoral and cellular immunity. In this issue of the JCI, Titanji and colleagues report that activated memory B (mBAct) cells are depleted in SIV-infected macaques defined as rapid progressors. Depletion was mediated by programmed death-1 (PD-1) and resulted in reduction of antibody titers specific for SIV and bacterial antigens. Interestingly, blockade of PD-1 in infected animals protected B cells from apoptosis and increased levels of SIV-specific antibodies in blood. These findings pave the way for a new therapeutic strategy aimed at improving humoral immunity in HIV-1 infection.

Authors

Francesca Chiodi

×

Total citations by year

Year: 2017 2015 2012 Total
Citations: 1 1 2 4
Citation information
This citation data is accumulated from CrossRef, which receives citation information from participating publishers, including this journal. Not all publishers participate in CrossRef, so this information is not comprehensive. Additionally, data may not reflect the most current citations to this article, and the data may differ from citation information available from other sources (for example, Google Scholar, Web of Science, and Scopus).

Citations to this article (4)

Title and authors Publication Year
Pathogenic Correlates of Simian Immunodeficiency Virus-Associated B Cell Dysfunction
E Brocca-Cofano, D Kuhrt, B Siewe, C Xu, GS Haret-Richter, J Craigo, C Labranche, DC Montefiori, A Landay, C Apetrei, I Pandrea, G Silvestri
Journal of virology 2017
Upregulation of Programmed Death-1 and Its Ligand in Cardiac Injury Models: Interaction with GADD153
B Baban, JY Liu, X Qin, NL Weintraub, MS Mozaffari, O Akbari
PloS one 2015
Programmed death 1 protects from fatal circulatory failure during systemic virus infection of mice
H Frebel, V Nindl, RA Schuepbach, T Braunschweiler, K Richter, J Vogel, CA Wagner, D Loffing-Cueni, M Kurrer, B Ludewig, A Oxenius
Journal of Experimental Medicine 2012
The Impact of Inflammation and Immune Activation on B Cell Differentiation during HIV-1 Infection
N Ruffin, PH Thang, B Rethi, A Nilsson, F Chiodi
Frontiers in immunology 2012

Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts